Compare Hilton Hotels Corporation Common Stock (HLT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.36 (market cap $72.76B), while Summit Therapeutics Inc trades at $17.43 (market cap $13.71B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 5.3× Summit Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Summit Therapeutics Inc for 16 Days on average.
| HLT | SMMT | |
|---|---|---|
Market Cap | $72.76B | $13.71B |
Volume | 1,148,634 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $26.38 |
52-Week Low | $256.96 | $12.43 |
Typical Hold Time | 138 Days | 16 Days |
Enterprise Value | $85.78B | $13.04B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $327.48, up 2.18% today, reflecting strong momentum near its recent highs. The stock shows a bullish technical setup with consistent earnings beats in recent quarters and solid revenue growth, with 2025 revenue reaching $12.04 billion. Analyst sentiment is positive, with a consensus price target of $348.11 and no sell ratings among 49 analysts. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook for HLT remains favorable, driven by robust travel demand, global portfolio expansion, and strong operational cash flow. Key risks include high debt levels, with a debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles. Upside potential hinges on continued execution and market share gains in high-growth regions like Asia, as noted in recent company reports.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
